Cancer Research UK welcomes cetuximab approval

In collaboration with the Press Association

Cancer Research UK has welcomed a decision by the Scottish heath regulator to approve cetuximab for the treatment of head and neck cancers.

The drug is the first new treatment for head and neck cancers in 20 years and has been shown to significantly improve survival rates when used alongside radiotherapy.

"This form of cancer can often be very difficult to treat, so any improvement in survival is a significant step forward," said medical director of Cancer Research UK professor John Toy.

"Head and neck cancer includes cancers of the mouth, nose and throat. The biggest risk factors for mouth cancer are age, smoking tobacco and regularly drinking four or more units of alcohol a day.

"Cancer Research UK's Open Up to Mouth Cancer campaign continues to raise awareness of the early signs and risk factors for mouth cancer, which is the most common form of head and neck cancer."

Find out more about different types of cancer